Hemotune

Hemotune is pioneering a magnetic nanoparticle separation platform with applications across healthcare and industrial bioprocessing. Its lead medical programs target enabling safer gene therapies by depleting neutralizing antibodies and treating sepsis through multi-target blood purification. The company operates as a private, platform-based biotech, leveraging its tunable HemoBead technology for both therapeutic and bioseparation partnerships.

Nanoengineered magnetic particles (HemoBeads) with tunable surface chemistry for highly selective capture and separation of specific targets (e.g., antibodies, cytokines, viruses) from complex fluids like blood, integrated into a medical device system (HemoSystem) for extracorporeal blood purification.

In blood purification, Hemotune competes with established adsorbent therapies like CytoSorbents' CytoSorb and Baxter's oXiris filter, differentiating on claimed multi-target precision. In gene therapy enabling, it faces emerging approaches like IgG-degrading enzymes. Its core competitive advantage is the tunable selectivity of its magnetic nanoparticle platform.